Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Hoffmann-La Roche
Eli Lilly and Company
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Astellas Pharma Inc
Amgen
GT Medical Technologies, Inc.
Genmab
Amgen
Amgen
AbbVie
University of Vermont
Daiichi Sankyo
Ruijin Hospital
M.D. Anderson Cancer Center
BriaCell Therapeutics Corporation
Rezolute
The Methodist Hospital Research Institute
Odense University Hospital
Bayer
Massachusetts General Hospital
M.D. Anderson Cancer Center
Resilience
University of Rome Tor Vergata
Federation Francophone de Cancerologie Digestive
Ottawa Hospital Research Institute
Fox Chase Cancer Center
Qinghai Red Cross Hospital
University of Aarhus
Sun Yat-sen University
Mabwell (Shanghai) Bioscience Co., Ltd.
NaviFUS Corporation
Blokhin's Russian Cancer Research Center
Qingdao Central Hospital
Surgimab
Tanta University